We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.
Find a trial
At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment, find a trial that might be suitable for you.
Use the search function below to find a clinical trial that may suit you and your cancer diagnosis
ADG206-1001
A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects with Advanced/Metastatic Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
REFOCUS RLY-4008-101
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
SKB264-II-06
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
OP-1250-002
A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)
Locations
Wesley, Southport
Diagnosis
Breast cancer
Open for recruitment
View Trial
SHR-A1921-I-102
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BGB-24714-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
RC198-G001
A Phase 1, First-In-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ATRIUM ATG-018-001
A Phase 1, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
CK-301-101
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
PXS5505-MF-101
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Locations
Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
DB-1303-O-1001
A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors. (DB-1303-O-1001)
Locations
South Brisbane
Diagnosis
Breast cancer, Endometrial cancer
Open for recruitment
View Trial
BGB-A317-A3055-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
STARSTRUCK 177Lu-TLX250-001
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and peposertib in Patients with Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ADG116-1003
A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BA3011-002
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor
Locations
Central Building (Oncology)
Diagnosis
Lung cancer
Open for recruitment
View Trial
ASPEN-06 AT148006
A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Locations
Southport
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
ASPEN 06
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Locations
Farrer Park
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
BRUIN MCL-321 / LOXO-BTK-20019
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Locations
Wesley, South Brisbane, Chermside, Southport, North Lakes
Diagnosis
Lymphoma – Hodgkin’s
Open for recruitment
View Trial
Viktoria-1 CELC-G-301
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Southport
Diagnosis
Breast cancer
Open for recruitment
View Trial
Viktoria-1
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
HERTHENA–Lung02
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy.
Locations
Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
View Trial
VERITAC-2 C4891001
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) VS Fulvestrant in Participants with Estrogen Receptor-Positive, HER-2-Negative Advanced Breast Cancer whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
SHR-2002-102
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
CS5001-101
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours, Lymphoma – B-cell Non Hodgkin’s, Lymphoma – T-Cell Non Hodgkin’s, Lymphoma – Hodgkin’s
Open for recruitment
View Trial
LM108-01-101
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
APG-2449-OG-101
A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer
Locations
South Brisbane
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
CAPTURE BCT1901
A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
CO44194
A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined with Nab-Paclitaxel compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Locations
Adelaide (Windsor Gardens)
Diagnosis
Breast cancer
Open for recruitment
View Trial
JAVELIN Bladder Medley
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy
Locations
Adelaide (Kurralta Park)
Diagnosis
Urothelial cancer
Open for recruitment
View Trial
INAVO121 WO43913
A Phase III, Multicenter, Randomized, Open-Label Study Evaluation the Efficacy and Safety of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer who Progressed during or after CDK4/6 Inhibitor and Endocrine Combination Therapy
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
SB221
A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients with Platinum-Resistant Ovarian Cancer
Locations
Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
STELLAR 303
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
KRYSTAL-12
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Lung cancer
Open for recruitment
View Trial
EvoPAR-Prostate01 D9723C00001
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Locations
Townsville, Chermside
Diagnosis
Prostate cancer
Open for recruitment
View Trial
HLX10-020-SCLC302
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Locations
Wesley
Diagnosis
Lung cancer
Open for recruitment
View Trial
ASCENT-07 GS-US-598-6168
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
Locations
Hobart, Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
BGB-A317-LBL-007-201
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
Locations
South Brisbane
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
KEYVIBE-010 MK-7684A-010
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma
Locations
Hobart
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
AK104-212
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
Locations
South Brisbane, Chermside
Diagnosis
Lung cancer
Open for recruitment
View Trial
AK112-101
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Locations
South Brisbane, Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours, Ovarian cancer
Open for recruitment
View Trial
RINGSIDE AL-DES-01
A Study of AL102 in Patients With Progressing Desmoid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Sarcoma
Open for recruitment
View Trial
BO43936
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Kidney cancer
Open for recruitment
View Trial
CA116-001 MORAb-202
A Study of MORAb-202 Versus Investigator’s Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Locations
Chermside
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
Relativity-106
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)
Locations
Farrer Park
Diagnosis
Liver cancer
Open for recruitment
View Trial
BBI-TP-3654-102
A Study of Oral TP-3654 in Patients With Myelofibrosis
Locations
Adelaide (Windsor Gardens)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
ABSK043-101
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BRIGHTLINE-1
A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Sarcoma
Open for recruitment
View Trial
AK127-101
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AML M22
AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.
Locations
South Brisbane, Wesley, Chermside, Southport
Diagnosis
Leukaemia
Open for recruitment
View Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
VNC-236-101
An Open-Label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP236 Monotherapy in Subjects with Advanced Cancer
Locations
South Brisbane, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Cancer-unknown origin
Open for recruitment
View Trial
DESTINY-B12 D9673C00007
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
CLINCH / ATG-022-ST-001
An Open, Multi-center, Phase I Clinical Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ALLG NBCR
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
BGB-A317-15025-101
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Locations
Adelaide (Windsor Gardens)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BRIGHTLINE-2 / 1403-0011
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LIBERATE
Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)
Locations
Epworth Richmond, Epworth Freemasons, Geelong
Diagnosis
Prostate cancer
Open for recruitment
View Trial
CONSOLE
Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial. (CONSOLE)
Locations
Wahroonga
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
DECREASE TROG 19.06
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Locations
Epworth Richmond
Diagnosis
Prostate cancer
Open for recruitment
View Trial
DASL-HiCaP ANZUP1801
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
Locations
Gold Coast University Hospital, Wahroonga, Gold Coast Private, Southport, Adelaide (Kurralta Park), Hobart
Diagnosis
Prostate cancer
Open for recruitment
View Trial
DREAM3R
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)
Locations
South Brisbane, Wesley, Chermside
Diagnosis
Mesothelioma
Open for recruitment
View Trial
PHI-101-001
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
EXPERT BCT1601
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)
Locations
Epworth Richmond
Diagnosis
Breast cancer
Open for recruitment
View Trial
ERUPT
External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)
Locations
Toowoomba
Diagnosis
Prostate cancer
Open for recruitment
View Trial
AMT-116-01
First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AMT-151-01
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HyperArc Registry VAR-2019-01
HyperArc Registry Study
Locations
Canberra, Greenslopes, Gold Coast Private, Maroochydore
Diagnosis
Brain cancer
Open for recruitment
View Trial
I-MAT MASC 03.18
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Locations
Hobart
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BOREAS KRT-232-101
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
Locations
South Brisbane, Wesley
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
MASTERPLAN
MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX and Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease
Locations
Gold Coast University Hospital
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
MRDR
Myeloma and Related Disease Registry
Locations
Wesley, South Brisbane, Chermside, Southport
Diagnosis
Multiple myeloma
Open for recruitment
View Trial
VNC-236-101
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
SLN124-004
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Locations
Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
ESCALADE D8227C00001
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤65 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Locations
South Brisbane, Wesley, Chermside, Southport
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
KRYSTAL-10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
HARMONY R3767-ONC-2011
Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Locations
Hobart
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
ARTISTRY-7 ALKS 4230-007
Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Locations
Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
KEYNOTE-867 MK-3475-867
Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
RADIANT / BAY 88-8223 / 20510
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Locations
Chermside, Wesley, South Brisbane, Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
ASCENT-04 GS-US-592-6173
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
ASCENT-03 GS-US-592-6238
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
TREMOR
Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)
Locations
Epworth Richmond
Diagnosis
Neurological conditions
Open for recruitment
View Trial
HBI-8000-303
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
Locations
Wesley, Chermside, Southport, South Brisbane, North Lakes
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
C-POST R2810-ONC-1788
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Locations
Southport, Adelaide (Kurralta Park)
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BGB-900-105
Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
Locations
South Brisbane, Adelaide (Windsor Gardens)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
CAPItello-280
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Locations
Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
COSTAR_213410
Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung)
Locations
North Lakes, Chermside, Wesley, Southport, South Brisbane
Diagnosis
Lung cancer
Open for recruitment
View Trial
KEYVIBE-006 MK-7684A-006
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
EVOKE-02 GS-US-576-6220
Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Locations
Adelaide (Windsor Gardens)
Diagnosis
Lung cancer
Open for recruitment
View Trial
BGB-A317-B167-101
Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
STELLAR-001
Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ASCEND CTC0304
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Locations
Wesley
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
ABCPro
Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.
Locations
Bowen Icon Cancer Centre
Diagnosis
Breast cancer
Open for recruitment
View Trial
TUGETHER BCT2102
Tucatinib together with Pembrolizumab and Trastuzumab: A Phase II, Two-Arm, Non-Comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab (MK-3475) and Trastuzumab in Patients with Pre-Treated Advanced HER2-Positive Breast Cancer
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
There are no clinical trials currently available